To the Editor

In the last issue of Cardiac Interventions Today, there was a nice review of percutaneous treatment options for mitral regurgitation (MR). However, there was a mistake regarding the Carillon Mitral Contour System. The authors misunderstood the echocardiographic data from the recent TITAN trial, a European safety and efficacy study.

In this trial, using quantitative echocardiographic parameters, we found that MR was reduced by an average of 40%, which is a different way of looking at MR changes, rather than at the more crude MR grade that is typically done. Unfortunately, in this review, it was mistakenly reported that 40% of patients had improvement in MR, which is not true. In fact, 80% of patients in TITAN had improvements in MR by one grade or more.

Steven L. Goldberg , MD
Director, Cardiac Catheterization Laboratory, University of Washington Medical Center; and Chief Clinical Officer, Cardiac Dimensions, Inc., in Kirkland, Washington.